Gyre Therapeutics Inc ( (GYRE) ) has released its Q4 earnings. Here is a breakdown of the information Gyre Therapeutics Inc presented to its investors.
Gyre Therapeutics Inc., a biotechnology company specializing in organ fibrosis, is advancing its commercial and clinical-stage portfolios with a focus on innovative treatments for liver fibrosis and other related conditions. The company’s recent earnings report highlights its strategic initiatives and financial performance for the fourth quarter and full year of 2024.
Gyre Therapeutics reported a net income of $17.9 million for the full year 2024, a significant turnaround from a net loss of $85.5 million in 2023. This improvement was driven by the absence of acquired in-process research and development expenses that impacted the previous year’s results. The company generated $105.8 million in revenues, with ETUARY sales contributing significantly despite a decline from the prior year due to economic fluctuations in China.
Key strategic developments include the anticipated commercial launch of nintedanib and avatrombopag in 2025, which are expected to drive revenue growth. Additionally, Gyre is progressing with its clinical trials, including the pivotal Phase 3 trial for CHB-associated liver fibrosis and the planned Phase 2 trial for MASH-associated liver fibrosis in the U.S. The company is also advancing its pipeline with several promising candidates in various stages of development.
Looking ahead, Gyre Therapeutics projects revenue growth of 11.3% to 20.8% for 2025, supported by new product launches and continued market penetration of existing treatments. The company’s management remains optimistic about its ability to execute its strategic initiatives and expand its market presence, leveraging its robust sales and marketing platform in the PRC.